CheckMate 214 Exploratory Biomarker Analysis: Predicting Response to Nivolumab Plus Ipilimumab in Advanced RCC

May 29-31, 2020; Online at meetings.asco.org/am
Biomarker evaluation suggests that prolonged PFS with nivo plus ipi may be associated with enhanced expression of genes involved in the tumor microenvironment and inflammatory responses; PD-L1 expression is not predictive for OS or PFS.
Format: Microsoft PowerPoint (.ppt)
File Size: 278 KB
Released: June 3, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Exelixis
Pfizer, Inc. and EMD Serono

Related Content

Dr Eric Jonasch discusses advances in the care of patients with renal cell carcinoma in this on-demand webcast from Clinical Care Options (CCO)

Naomi B. Haas, MD
Program Director
Eric Jonasch, MD
Program Director
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: January 26, 2023 Expired: January 25, 2024

Experts provide their thoughts on key data in breast, gynecologic, renal cell, urothelial, lung, hepatobiliary, and skin cancers presented at the 2022 ESMO Congress, from Clinical Care Options (CCO)

Nicoletta Colombo, MD Robert Motzer, MD person default Sapna P. Patel, MD David Planchard, MD, PhD Elizabeth R. Plimack, MD, MS Rachna Shroff, MD, MS Sara Tolaney, MD, MPH Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: November 14, 2022 Expired: November 13, 2023

Download these expert-selected slides on treatments for early and later-stage renal cell carcinoma.

Naomi B. Haas, MD
Program Director
Eric Jonasch, MD
Program Director
Katy Beckermann, MD, PhD Elizabeth R. Plimack, MD, MS
Released: October 21, 2022

Phase III COSMIC-313: addition of cabozantinib to nivolumab plus ipilimumab in previously untreated patients with IMDC intermediate- or poor-risk advanced RCC, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 22, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings